Global Locations

Pazopanib

ISO 17034:
Catalog Number : CS-O-02101
CAS Number : 444731-52-6
Status : Available for immediate dispatch
List Price Online Price Size Stock Status Quantity

Custom Quote

Send us a request for Custom
pack size and pricing.

Synthesis Advice

Schedule a call with our Experts to
answer your questions.

Instant Help

Connect with our Live Chat
representatives for instant help.

Chemical Information

Chemical Name : Pazopanib
Category : API Standards
Purity : Not less than 95 %
Molecular Weight : 437.52 mol/g
Molecular Formula : C₂₁H₂₃N₇O₂S
Application : "Pazopanib is a Kinase Inhibitor. The mechanism of action of pazopanib is as a Protein Kinase Inhibitor, and Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 2D6 Inhibitor, and Cytochrome P450 2C8 Inhibitor."
Therapeutic : Anti-Cancer / Oncology

Shipping & Availability

Status: : Available for immediate dispatch
COA :
[Login Needed]
MSDS :
[Login Needed]
Hazardous Compound : No

Purchase Options

Payment mode : Credit / Debit / Purchase Order
Taxes : All prices are inclusive taxes
Refund Policy : 30 days money back guarantee

Additional Information


Medical uses

References : "Pharmaceutical Benefits Scheme, Australian Government, Retrieved 27 January 2014; GlaxoSmithKline, 31 March 2014, "
Canonical SMILES : CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Isomeric SMILES : CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
InChI : InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
InchIKey : CUIHSIWYWATEQL-UHFFFAOYSA-N
IUPAC Name : 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
Exact Mass : 437.16339418
Solubility : In water, 3.3 mg/L at 25 °C (est)
Use Classification : Human drugs -> Votrient -> EMA Drug Category
Description : Pazopanib is a pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor, a vascular endothelial growth factor receptor antagonist and an angiogenesis modulating agent. It is a member of indazoles, an aminopyrimidine and a sulfonamide. It is a conjugate base of a pazopanib(1+).
Disposal Methods : SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
Vapor Pressure : 3.21X10-14 mm Hg at 25 °C (est)
Toxicity Summary : IDENTIFICATION AND USE: Pazopanib is a white to slightly yellow solid formulated into film-coated tablets. Pazopanib, an inhibitor of multiple receptor tyrosine kinases, is an antineoplastic agent. It is used for the treatment of advanced renal cell carcinoma and for patients with advanced soft tissue sarcoma who have received prior chemotherapy. HUMAN EXPOSURE AND TOXICITY: Severe or fatal hepatotoxicity, manifested as increases in serum concentrations of aminotransferases and bilirubin, has been reported in patients receiving pazopanib. If hepatotoxicity occurs, pazopanib dosage should be reduced, or therapy should be interrupted or permanently discontinued. Woman should avoid the use of pazopanib during pregnancy. While there are no adequate and well-controlled studies in pregnant women, pazopanib has been shown to be teratogenic, embryotoxic, fetotoxic, and abortifacient in animal studies. If used during pregnancy or if the patient becomes pregnant while receiving pazopanib, the patient should be apprised of the potential fetal hazard. Prolongation of the QT interval and torsades de pointes and severe and sometimes fatal hemorrhage events have been reported in patients receiving pazopanib. Finally, GI perforation or fistula which can be fatal has also been associated with the use of pazopanib. ANIMAL STUDIES: While carcinogenicity studies with pazopanib have not been conducted, in a 13-week study in mice, proliferative lesions in the liver including eosinophilic foci occurred in 2 females and a single case of adenoma in another female was observed at a dose of 1000 mg/kg/day. Pazopanib produced fetal teratogenic effects (including cardiovascular malformations and delayed ossification), reduced fetal body weight, and embryo lethality in rats at a dose level as low as 3 mg/kg/day. In rabbits, maternal toxicity (body weight loss, reduced food consumption, and abortion) was observed at doses as low as 30 mg/kg/day, while fetal weight was reduced at doses as low as 3 mg/kg/day. Pazopanib also reduced fertility in female rats at a dose of 300 mg/kg. Increased pre- and post-implantation loss and early resorptions were noted at doses as low as 10 mg/kg/day. Decreased corpora lutea were observed in monkeys and mice and ovarian atrophy was noted in rats. While pazopanib did not affect mating or fertility in male rats, reductions in sperm production rates, sperm motility, and epididymal and testicular sperm concentration was observed at doses as low as 100 mg/kg/day for 15 weeks. Following 26 weeks of dosing, male rats given doses of 30 mg/kg/day or greater exhibited decreased testicular and epididymal weights, atrophy and degeneration of the testes with aspermia, hypospermia and cribriform change in the epididymis. In toxicology studies in rats, there were effects in a variety of tissues (bone, teeth, bone marrow, nail beds, reproductive organs, hematological tissues, kidney, adrenal glands, lymph node, pituitary, and pancreas) consistent with vascular endothelial growth factor receptor (VEGFR) inhibition and/or disruption of VEGF signaling pathways with some effects occurring at doses of 3 mg/kg/day. Pazopanib was tested in a standard battery of genotoxicity studies. Pazopanib was found to be nonmutagenic and non-clastogenic when tested in a bacterial cell (Ames) assay, human peripheral lymphocyte chromosome aberration assay and rat micronucleus assay.
Antidoteand Emergency Treatment : /SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
Human Toxicity Excerpts : /SIGNS AND SYMPTOMS/ Severe or fatal hepatotoxicity, manifested as increases in serum concentrations of aminotransferases (ALT (SGPT), AST (SGOT)) and bilirubin, has been reported in patients receiving pazopanib.

Related compounds of Pazopanib

CAT NO. COMPOUND CAS NO. CATEGORY
CS-CW-00177 Pazopanib hydrochloride 635702-64-6 API Standards